Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples fo tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in tissue samples from patients with acute promyelocytic leukemia.

Detailed Description
-----------------
OBJECTIVES: Demonstrate that S100A10 is expressed on APL cells and that levels of S100A10 correspond to the amount of fibrinolytic activity. Evaluate the impact of ATRA on S100A10 level and fibrinolytic activity in vitro. Evaluate the impact of S100A10 knockdown on fibrinolytic activity. Correlate in vitro findings in cell culture to primary patient samples both pre- and post-ATRA therapy. OUTLINE: This is a multicenter study. Previously collected samples are analyzed via flow cytometry and western blot analysis. Cell surface levels of S100A10 and annexin A2 are correlated to the promyelocyte population and total protein levels are examined to determine total annexin A2 and S100A10 in acute promyelocytic leukemia cells.

Official Title
-----------------
Regulation of S100A10 by the PML-RAR-alpha Oncoprotein

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: protein expression analysis
* Genetic: western blotting
* Other: flow cytometry
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of acute promyelocytic leukemia Available cryopreserved cells from diagnosis or cryopreserved cells from remission (germline) PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: protein expression analysis|nan|
|Genetic: western blotting|nan|
|Other: flow cytometry|nan|
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demonstration that S100A10 is expressed on acute promyelocytic leukemia cells and that levels of S100A10 correspond to the amount of fibrinolytic activity |  |  | 
| Evaluation of the impact of all-trans retinoic acid (ATRA) on S100A10 level and fibrinolytic activity in vitro |  |  | 
| Evaluation of the impact of S100A10 knockdown on fibrinolytic activity |  |  | 
| Correlation of in vitro findings in cell culture to primary patient samples both pre- and post-ATRA therapy |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute promyelocytic leukemia (M3), childhood acute promyelocytic leukemia (M3), adult acute myeloid leukemia in remission, untreated adult acute myeloid leukemia, childhood acute myeloid leukemia in remission, untreated childhood acute myeloid leukemia and other myeloid malignancies